Adaptive Phage Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Therapeutic development directed at infections caused by multidrug-resistant bacteria.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Adaptive Phage Therapeutics is founded in Gaithersburg, Maryland as a clinical-stage company developing phage-based therapies to combat multi-drug-resistant bacterial infections, with an expanding library of bacteriophages designed to adapt to emerging bacterial resistance.
- Later-stage funding
The company closes a Series B in April 2022 and a Series B1 in June 2023, advancing its clinical-stage phage therapy programs.
- Merger with BiomX
On March 15, 2024, Adaptive Phage Therapeutics completes its merger with BiomX Inc. in a stock-for-stock transaction: BiomX's former shareholders own about 55% and APT's former shareholders about 45% of the combined company, which keeps the BiomX name and carries two Phase 2 phage-therapy assets forward; a concurrent $50 million private placement funds the combined pipeline.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.